Table 3.

Adjusted odds of dying from CVD conferred by increased or decreased biomarker concentrations comparing 211 cases with 253 controls: MHS 1990–1992 and 1995–1997.

	Full modela		Final modelb
Biomarker	OR (95% CI)	P	OR (95% CI)	P
MR-proANP, >85.2 pmol/L	1.00 (0.39–2.54)	0.99	–	–
ST2, decreasedc	2.03 (1.01–4.08)	0.05	1.92 (1.05–3.48)	0.03
Copeptin >11.25 pmol/L	0.92 (0.36–2.37)	0.87	–	–
NT-proBNP, increasedd	4.81 (1.52–15)	0.007	5.67 (2.17–15)	<0.001
hs-CRP >3.0 mg/L	1.88 (1.03–3.43)	0.04	1.73 (1.03–2.89)	0.04
hs-cTnI, >10.1 ng/L	6.29 (1.09–36)	0.04	8.53 (1.68–43)	0.01

^aFull model adjusted for age, sex, race, education, study year, smoking, systolic blood pressure, total cholesterol, abdominal obesity, diabetes, previous hospitalization for cardiovascular events, and biomarkers hs-CRP, NT-proBNP, ST2, MR-proANP, copeptin, and hs-cTnI.

^bFinal model adjusted for age, sex, race, education, study year, smoking, systolic blood pressure, total cholesterol, abdominal obesity, diabetes, previous hospitalization for cardiovascular events, and biomarkers ST2, hs-CRP, NT-proBNP, and hs-cTnI.

^cST2: males <30.6 U/mL, females <20.9 U/mL.

^dNT-proBNP: <50 years <450 ng/L, > 50 years >900 ng/L